-
Dorsal brain activity reflects the severity of menopausal symptoms. Menopause (IF 2.7) Pub Date : 2024-04-16 Kohei Nakamura, Hideyuki Hoshi, Momoko Kobayashi, Keisuke Fukasawa, Sayuri Ichikawa, Yoshihito Shigihara
The severity of menopausal symptoms, despite being triggered by hormonal imbalance, does not directly correspond to hormone levels in the blood; thus, the level of unpleasantness is assessed using subjective questionnaires in clinical practice. To provide better treatments, alternative objective assessments have been anticipated to support medical interviews and subjective assessments. This study aimed
-
Sexually transmitted infections in midlife women. Menopause (IF 2.7) Pub Date : 2024-04-16 Elizabeth Micks
Rates of sexually transmitted infections (STIs) are increasing in all age groups. Although STI incidence decreases with age, midlife women have risk factors that may lead to STI acquisition and underdiagnosis. Clinicians may assume that older women are not sexually active. Although many STIs are asymptomatic, when midlife women do experience vaginal symptoms, they may be erroneously attributed to menopause
-
Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2). Menopause (IF 2.7) Pub Date : 2024-04-16 Rossella E Nappi, Kimball A Johnson, Petra Stute, Martin Blogg, Marci English, Antonia Morga, Ludmila Scrine, Emad Siddiqui, Faith D Ottery
The aims of the study were to further characterize the efficacy of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause using responder analysis and to investigate whether efficacy, not adjusted for placebo, resulted in clinically meaningful within-patient change.
-
Socioecological factors influencing physical activity engagement for women across the menopausal transition: a systematic review. Menopause (IF 2.7) Pub Date : 2024-04-09 Meghan Casey, Elissa Dabkowski, Ma Regina L de Gracia, Kathleen A Moore, Gerard A Kennedy, Joanne E Porter, Yasmina Nasstasia, Marlies E Alvarenga
Physical activity during menopause can be effective in reducing the physiological changes associated with reproductive aging that increase risks for noncommunicable diseases, yet many women do not meet the recommendations for physical activity.
-
Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses. Menopause (IF 2.7) Pub Date : 2024-04-09 Seo H Baik, Fitsum Baye, Clement J McDonald
The study aims to assess the use of menopausal hormone therapy beyond age 65 years and its health implications by types of estrogen/progestogen, routes of administration, and dose strengths.
-
Daily spiritual experiences and allostatic load trajectories: a longitudinal study of midlife African American women. Menopause (IF 2.7) Pub Date : 2024-04-09 Elizabeth Williams, Latesha K Harris, Shuo Zhang, Yamnia I Cortés
This study aimed to evaluate the association between daily spiritual experiences and allostatic load (AL) trajectories in midlife African American women.
-
Does everyday discrimination account for the increased risk of vasomotor symptoms in Black women?: the Study of Women's Health Across the Nation (SWAN). Menopause (IF 2.7) Pub Date : 2024-04-09 Alexis N Reeves, Tené T Lewis, Michelle M Hood, Rebecca C Thurston, Nancy E Avis, Sherri-Ann M Burnett-Bowie, Yamnia I Cortés, Genevieve Neal-Perry, Siobán D Harlow
Vasomotor symptoms (VMS), including hot flashes and night sweats, are hallmark symptoms of the menopause transition. Previous research has documented greater frequency, duration, and severity of VMS in Black women compared with women from other racial/ethnic groups, even after accounting for other factors. This analysis examined the association between discrimination and VMS and the extent to which
-
Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause. Menopause (IF 2.7) Pub Date : 2024-04-03 JoAnn V Pinkerton, James Simon, Nick Panay, Christian Seitz, Susanne Parke, Cecilia Caetano, Uwe Mellinger, Nazanin Haseli Mashhadi, Claudia Haberland, Gordana Atanackovic, Cornelia Holz, Guangping Mao, Marina Morrison, Sven Nisius, Matthias Schaefers, Lineke Zuurman
Elinzanetant is a selective neurokinin-1,3 receptor antagonist in development for the treatment of vasomotor symptoms (VMS) associated with menopause. The pivotal, double-blind, randomized, placebo-controlled phase 3 studies Overall Assessment of efficacy and Safety of elinzanetant In patients with vasomotor Symptoms (OASIS) 1 and 2 will assess the efficacy and safety of elinzanetant in women with
-
Nutrition knowledge, attitudes, and perceptions of Greek menopausal women. Menopause (IF 2.7) Pub Date : 2024-04-03 Evgenia-Ioanna Papadima, Tonia Vassilakou, Themos Grigoriadis, Anastasios Boutsiadis, Sofia Ivanidou, Andreas Kalampalikis, Lina Michala
Nutritional guidelines for postmenopausal women differ. This study aimed to assess postmenopausal women's knowledge, beliefs, and practices regarding nutrition during menopause and their dietary habits.
-
What do we know about the role of menopause in cardiovascular autonomic regulation in hypertensive women? Menopause (IF 2.7) Pub Date : 2024-04-03 Stella V Philbois, Tabata P Facioli, Izabella De Lucca, Ana C Veiga, Naiara Chinellato, Marcus V Simões, Jens Tank, Hugo C D Souza
We investigated the systemic arterial hypertension effects on cardiovascular autonomic modulation and baroreflex sensitivity (BRS) in women with or without preserved ovarian function.
-
The influence of habitual physical activity and sedentary behavior on objective and subjective hot flashes at midlife. Menopause (IF 2.7) Pub Date : 2024-03-25 Sarah Witkowski, Quinn White, Sofiya Shreyer, Daniel E Brown, Lynnette Leidy Sievert
The purpose of this study was to evaluate relationships between physical activity, sedentary time, and hot flashes during both waking and sleeping periods using concurrent objective and subjective measures of hot flashes in midlife women.
-
Postmenopausal endometriosis: a challenging condition beyond menopause. Menopause (IF 2.7) Pub Date : 2024-03-25 Alexandre Vallée, Marie Carbonnel, Pierre-François Ceccaldi, Anis Feki, Jean-Marc Ayoubi
Postmenopausal endometriosis is a complex condition that challenges the conventional belief that endometriosis resolves with menopause. Despite the cessation of menstruation, a subset of women continues to experience or develop endometriosis-related symptoms during the postmenopausal period. Thus, this review aimed to shed light on postmenopausal endometriosis, exploring its clinical features, diagnostic
-
"Not feeling like myself" in perimenopause - what does it mean? Observations from the Women Living Better survey. Menopause (IF 2.7) Pub Date : 2024-03-25 Nina Coslov, Marcie K Richardson, Nancy Fugate Woods
This study aimed to understand the meaning of the phrase "not feeling like myself" (NFLM) when used by those on the path to menopause by exploring the relationship of symptoms reported to ratings of NFLM.
-
Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2). Menopause (IF 2.7) Pub Date : 2024-3-22 Nanette Santoro, Rossella E Nappi, Genevieve Neal-Perry, Marci English, Deanna D King, Yusuke Yamaguchi, Faith D Ottery
This study aimed to assess the efficacy of the neurokinin 3 receptor antagonist, fezolinetant, according to several intrinsic (individual related) and extrinsic (external influence) factors that may influence the frequency and severity of moderate-to-severe vasomotor symptoms (VMS) using pooled 12-week data from SKYLIGHT 1 and 2.
-
Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause. Menopause (IF 2.7) Pub Date : 2024-03-12 Nicole E Cieri-Hutcherson, Elaine K Marji, Timothy C Hutcherson
Vasomotor symptoms (VMS) affect many postmenopausal persons and impact sleep and quality of life.
-
Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause (IF 2.7) Pub Date : 2024-03-05 Maria D Hurtado, Elif Tama, Sima Fansa, Wissam Ghusn, Diego Anazco, Andres Acosta, Stephanie S Faubion, Chrisandra L Shufelt
To compare weight loss response and changes in cardiometabolic risk markers in postmenopausal women using semaglutide with and without menopause hormone therapy (HT) use.
-
Effects of sports therapy on improvement of menopausal symptoms, psychological status, and body morphology in perimenopausal women. Menopause (IF 2.7) Pub Date : 2024-03-05 Sun Mi Kim, Yongwoo Ko, Da Seol Kim, Na Yeon Kim, Hyun Chan Hwang, Doug Hyun Han
The aim of this study was to increase the treatment rate of perimenopausal women by providing evidence-based nonpharmaceutical treatments through developing scientific evidence-based sports therapy and verifying its effectiveness.
-
Body composition, physical activity, and menopause symptoms: how do they relate? Menopause (IF 2.7) Pub Date : 2024-03-05 Sam R Moore, Hannah E Cabre, Abbie E Smith-Ryan
This study characterized the impact of physical activity (light, moderate, and vigorous [VIG] active minutes per day) and body composition (percent body fat [%BF] and fat-free mass index) on total menopausal symptoms (TMSs) in 72 premenopausal, perimenopausal (PERI), or postmenopausal women.
-
Navigating menopause at work: a preliminary study about challenges and support systems. Menopause (IF 2.7) Pub Date : 2024-03-05 Elisabet Alzueta, Luca Menghini, Laila Volpe, Fiona C Baker, Ann Garnier, Philip M Sarrel, Massimiliano de Zambotti
Women's increasing workforce participation necessitates understanding unique life phases like menopause for enhanced workplace inclusivity. This research investigates the challenges and needs of peri-menopausal women in work settings, using the Job Demands-Resources model as a foundation.
-
Association between neighborhood poverty and ovarian reserve: the ovarian aging study. Menopause (IF 2.7) Pub Date : 2024-03-05 Anwesha Pan, Kyle D Crowder, Marcelle I Cedars, Maria E Bleil
This study aimed to examine the association between neighborhood poverty and ovarian reserve.
-
A prospective study on the relationship between polycystic ovary syndrome and age at natural menopause. Menopause (IF 2.7) Pub Date : 2024-2-27 Mina Amiri, Maryam Rahmati, Faegheh Firouzi, Fereidoun Azizi, Fahimeh Ramezani Tehran
This study aimed to determine whether polycystic ovary syndrome (PCOS) was associated with age at menopause, compared with women without PCOS, after adjusting for potential confounders.
-
Association between lumbar muscle size and bone mineral density in nonfractured postmenopausal women with and without osteoporosis. Menopause (IF 2.7) Pub Date : 2024-02-27 Chun-Han Hou, Tsyh-Jyi Hsieh, Ming-Chung Chou
Estrogen deficiency in postmenopausal women is associated with bone loss and a decline in muscle mass. However, the associations between lumbar muscle size and bone mineral density (BMD) in postmenopausal women with and without osteoporosis remain unclear. The aim of this study was to investigate the associations between lumbar muscle size and BMD in nonfractured postmenopausal women with osteoporosis
-
Comparison of the effect of noninvasive radiofrequency with vaginal estrogen and vaginal moisturizer in the treatment of vulvovaginal atrophy in postmenopausal women: a randomized clinical trial. Menopause (IF 2.7) Pub Date : 2024-02-27 Anna Valéria Gueldini de Moraes, Lucia Costa-Paiva, Helymar da Costa Machado, Tayná Figueiredo Maciel, Fernanda Viviane Mariano, Adriana Orcesi Pedro
To compare the effect of noninvasive radiofrequency (RF) with vaginal estrogen (E), and vaginal moisturizer (M) on improving vulvovaginal atrophy (VVA) in women with genitourinary syndrome of menopause.
-
Climacteric status at age 46 is associated with poorer work ability, lower 2-year participation in working life, and a higher 7-year disability retirement rate: a Northern Finland Birth Cohort 1966 study. Menopause (IF 2.7) Pub Date : 2024-02-27 Tiia Saarinen, Susanna M Savukoski, Paula Pesonen, Eeva Vaaramo, Jaana Laitinen, Tuulia Varanka-Ruuska, Leena Ala-Mursula, Maarit Niinimäki
To study the association between an advanced climacteric status at 46 years of age and current perceived work ability, the consequent 2-year accumulation of disability and unemployment days, and the 7-year incidence of disability pensions.
-
Circulating cell-free DNA is elevated in postmenopausal compared with pre- and perimenopausal women. Menopause (IF 2.7) Pub Date : 2024-2-22 Teagan Fisher, Elyse Powell, Nicole L Yuwono, Caroline E Ford, Kristina Warton
With the rising use of circulating cell-free DNA (cirDNA) liquid biopsies for disease screening, it is important to understand biological differences that may impact the accuracy of cirDNA-based clinical tests. Although a number of biological factors have been researched, the relationship between menopause and cirDNA has not been thoroughly investigated. We aimed to compare plasma cirDNA concentration
-
Age at natural or surgical menopause, all-cause mortality, and lifespan among postmenopausal women in the United States. Menopause (IF 2.7) Pub Date : 2024-2-22 Zailing Xing, Russell S Kirby
This study investigated the association of age at natural menopause with or without undergoing hysterectomy and/or bilateral oophorectomy after menopause and age at surgical menopause with all-cause mortality and lifespan in postmenopausal women.
-
Estradiol associations with brain functional connectivity in postmenopausal women. Menopause (IF 2.7) Pub Date : 2024-2-22 Abigail A Testo, Jenna Makarewicz, Elizabeth McGee, Julie A Dumas
Previous studies have found that estrogens play a role in functional connectivity in the brain; however, little research has been done regarding how estradiol is associated with functional connectivity in postmenopausal women. The purpose of this study was to examine the relationship between estradiol and functional connectivity in postmenopausal women.
-
Prevalence and risk factors associated with diabetes mellitus among middle-aged women in southern Brazil: a population-based study. Menopause (IF 2.7) Pub Date : 2024-2-22 Karen Oppermann, Poli M Spritzer
To investigate prevalence and clinical factors associated with diabetes among middle-aged women.
-
Fractional CO2 laser for genitourinary syndrome of menopause: evaluating the evidence. Menopause (IF 2.7) Pub Date : 2024-2-22 Jen Gunter
The fractionated CO2 laser has been marketed to women for a variety of gynecologic symptoms and conditions, including the genitourinary syndrome of menopause (GSM). The evidence has been limited, precluding conclusions regarding the efficacy and safety of the therapy. However, data from randomized, controlled trials evaluating this technology for GSM are now available. This Practice Pearl addresses
-
Eligibility criteria for using menopausal hormone therapy in breast cancer survivors: a safety report based on a systematic review and meta-analysis. Menopause (IF 2.7) Pub Date : 2024-2-22 Pluvio J Coronado, Ana Gómez, Eva Iglesias, María Fasero, Laura Baquedano, Sonia Sánchez, Isabel Ramírez-Polo, Esther de la Viuda, Borja Otero, Plácido Llaneza, Nicolás Mendoza, Daniel M Lubián
Menopause hormone therapy (MHT) effectively alleviates menopausal symptoms. However, it is generally not recommended for breast cancer survivors, although the scientific evidence is scarce.
-
A cross-sectional study of the association between breastfeeding history and overweight/obesity in postmenopausal women. Menopause (IF 2.7) Pub Date : 2024-02-20 Ting Ran, Nianchun Peng, Miao Zhang, Ying Hu, Huijun Zhuang, Tian Zhang, Juan He, Lixin Shi, Qiao Zhang, Jing Zheng
This study endeavors to augment comprehension of the association between breastfeeding and maternal weight within Asian populations.
-
Does menopause hormone therapy improve symptoms of depression? Findings from a specialized menopause clinic. Menopause (IF 2.7) Pub Date : 2024-02-20 Rahavi Gnanasegar, Wendy Wolfman, Leticia Hernandez Galan, Amie Cullimore, Alison K Shea
Depressive symptoms are commonly reported during the perimenopause and in the early postmenopausal years. Although menopausal hormone therapy (MHT) is considered the most effective treatment option for vasomotor symptoms, its effect on mood-related symptoms is less established. This study aims to assess interval change in depressive symptoms after initiation of MHT treatment in women seeking care at
-
Physical activity and menopausal symptoms: evaluating the contribution of obesity, fitness, and ambient air pollution status. Menopause (IF 2.7) Pub Date : 2024-02-20 Steriani Elavsky, Michal Burda, Lukáš Cipryan, Petr Kutáč, Marek Bužga, Vera Jandačková, Sy-Miin Chow, Daniel Jandačka
The menopausal transition is accompanied by transient symptoms that have been linked to subclinical cardiovascular disease (CVD); CVD has also been linked to air pollution. Physical activity (PA) reduces CVD, improves body composition, and can reduce menopausal symptoms. The purpose of this study was to assess the links between PA and menopausal symptoms and whether obesity, fitness, and air pollution
-
The association of depressive symptoms and female sexual functioning in the menopause transition: a cross-sectional study. Menopause (IF 2.7) Pub Date : 2024-02-13 Emily B Stevens, Wendy Wolfman, Leticia Hernandez-Galan, Alison K Shea
Sexual dysfunction is very common among middle-aged females. Several factors are considered to influence sexual functioning, including reproductive aging and associated physiological changes as well as life stressors, mental health, and other socioeconomic influences. The objectives of this study are to evaluate the effect of current depressive symptoms on sexual functioning during menopause and to
-
Propulsive forces and muscle activation during gait: comparisons between premenopausal and postmenopausal midlife women. Menopause (IF 2.7) Pub Date : 2024-02-13 Giovanni Gondim Tomaz, Markus Vinicius Campos Souza, Marcelo Augusto da Silva Carneiro, Mariana Luíza de Lima, Claudio Oliveira Assumpção, Fábio Lera Orsatti
The aim of this study was to investigate whether there is a reduction in propulsive force during gait in postmenopausal women compared with premenopausal women.
-
Migraines, vasomotor symptoms, and cardiovascular disease in the Coronary Artery Risk Development in Young Adults study. Menopause (IF 2.7) Pub Date : 2024-02-13 Catherine Kim, Pamela J Schreiner, Zhe Yin, Rachael Whitney, Stephen Sidney, Imo Ebong, Deborah A Levine
To examine whether vasomotor symptoms (VMS) and migraine headaches, hypothesized to be vasoactive conditions, are associated with greater risk for cardiovascular disease (CVD) events including strokes.
-
Prospective early adulthood risk factors for vasomotor symptoms in the Coronary Artery Risk Development in Young Adults study. Menopause (IF 2.7) Pub Date : 2024-1-25 Catherine Kim, Abbi Lane, Thanh-Huyen T Vu, Cora B Lewis, Zhe Yin, Hui Jiang, Richard J Auchus, Pamela J Schreiner
Previous studies have assessed potential risk factors for vasomotor symptoms (VMS) beginning in midlife. We examined whether early adulthood risk factors predict VMS trajectories over time.
-
Does hormone therapy exacerbate other venous thromboembolism risk factors? Menopause (IF 2.7) Pub Date : 2024-1-25 Laura Porterfield, John W Davis, Susan C Weller, Lu Chen, Gregg Wilkinson
Postmenopausal symptoms in women at higher risk for venous thromboembolism (VTE) due to comorbidities are often undertreated because of concerns that hormone therapy (HT) may increase VTE risk; however, it is unclear how much HT impacts risk of VTE when compared with other risk factors.
-
A prospective study on the relationship between polycystic ovary syndrome and age at natural menopause. Menopause (IF 2.7) Pub Date : 2024-1-25 Mina Amiri, Maryam Rahmati, Faegheh Firouzi, Fereidoun Azizi, Fahimeh Ramezani Tehran
This study aimed to determine whether polycystic ovary syndrome (PCOS) was associated with age at menopause, compared with women without PCOS, after adjusting for potential confounders.
-
The efficacy of purified pollen extract for reducing vasomotor symptoms in women: a systematic review and meta-analysis. Menopause (IF 2.7) Pub Date : 2024-01-09 Erica L Acquarulo, Emily C Hernandez, Fatbardha Kodzodziku, Eric C Nemec
Menopause impacts the quality of life for women, with symptoms varying from hot flashes to night disturbances. When menopausal hormonal therapy is contraindicated or women refuse menopausal hormonal therapy, many consider alternatives such as pollen extract for treating vasomotor symptoms.
-
Prolactinoma in postmenopausal women: a systematic review. Menopause (IF 2.7) Pub Date : 2024-01-09 Marcela Souza Carneiro, Ticiana Aparecida Alves de Mira, Daniela Angerame Yela, Cristina Laguna Benetti-Pinto
Prolactinomas occurring during the reproductive period exhibit a characteristic behavior. There are, however, gaps in the literature regarding the behavior of these tumors after menopause.
-
The relationship between depressive symptoms and physical performance in postmenopausal women: a cross-sectional investigation. Menopause (IF 2.7) Pub Date : 2023-12-19 Rosely M Silva, Fábio L Orsatti, Luana R Margato, Wellington G de Sousa, Danyelle C S Pelet, Jonathã Luiz Justino da Silva, Anderson D de Sousa Lino, Cláudio de Oliveira Assumpção, Markus Vinicius C Souza
The relationship between depressive symptoms and declining physical performance in postmenopausal women has been extensively examined. However, various confounding factors can influence this association. This study aimed to investigate the link between depressive symptoms and physical performance in postmenopausal women while considering potential interfering factors.
-
The association of menopause with cardiometabolic disease risk factors in low- and middle-income countries: a systematic review and meta-analyses. Menopause (IF 2.7) Pub Date : 2023-12-19 Raylton P Chikwati, Tinashe Chikowore, Nasrin Goolam Mahyoodeen, Nicole G Jaff, Jaya A George, Nigel J Crowther
Menopause is an integral part of women's health, and studies in high-income countries have shown an increase in cardiometabolic disease (CMD) risk factors in postmenopausal compared with premenopausal women. However, to date, no study has combined and assessed such studies across low- and middle-income countries. This would better inform early monitoring and intervention strategies for reducing CMD
-
Sleep and rest-activity rhythms for women at different menopausal statuses: the role of mental health. Menopause (IF 2.7) Pub Date : 2023-12-19 Szu-Yu Hou, Ching-Ju Chiu, Jeanne Laraine Shea, Chih-Liang Wang, Hsiao-Han Tang, Po-Ching Kuo, Yi-Chieh Yang, Hsin-Ping Hsu
To examine how mental health interplays with menopausal status in relation to sleep patterns and rest-activity rhythms (RARs) among middle-aged women.
-
Bone mass, fracture risk, and associated factors in postmenopausal women living with HIV. Menopause (IF 2.7) Pub Date : 2023-12-19 Paula R Leite-Silva, Rebeca S Pinheiro, João M B Barbosa-Ferreira, Antonio Balieiro, Meritxell Sabidó, Marcus V G Lacerda, Yury O Chaves, Paulo A Nogueira, Adele S Benzaken
The aim of this study was to assess the prevalence of low bone mass (osteopenia/osteoporosis), the factors associated with low bone mass, and the risk of fractures in Brazilian postmenopausal women living with HIV (WLH) in the Amazon region.
-
Assessing the robustness of muscle strength and physical performance measures in women older than 40 years: a test-retest reliability study. Menopause (IF 2.7) Pub Date : 2023-12-12 Sebastião Henrique Assis Silva, Fábio L Orsatti, Mariana L de Lima, Augusto C de Q Freitas, Marcelo A S Carneiro, Cláudio de Oliveira Assumpção, Markus Vinicius C Souza
This study investigated the test-retest reliability and minimal detectable change (MDC) of muscle strength and physical performance tests in women older than 40 years.
-
Treatment-induced menopause symptoms among women with breast cancer undergoing chemotherapy in China: a comparison to age- and menopause status-matched controls. Menopause (IF 2.7) Pub Date : 2023-12-12 Di Zhao, Qinghua Ma, Guopeng Li, Rui Qin, Yingtao Meng, Ping Li
Whether women with breast cancer experience more severe menopause symptoms than comparison women without a history of breast cancer diagnosis remains unclear. We aimed to investigate whether women with breast cancer undergoing chemotherapy experience more severe menopause symptoms than comparison women and explore various factors influencing menopause symptoms in women with breast cancer undergoing
-
The menopause-related gut microbiome: associations with metabolomics, inflammatory protein markers, and cardiometabolic health in women with HIV. Menopause (IF 2.7) Pub Date : 2023-12-12 Yi Wang, Anjali Sharma, Kathleen M Weber, Elizabeth Topper, Allison A Appleton, Deborah Gustafson, Clary B Clish, Robert C Kaplan, Robert D Burk, Qibin Qi, Brandilyn A Peters
This study aimed to identify menopause-related gut microbial features, as well as their related metabolites and inflammatory protein markers, and link with cardiometabolic risk factors in women with and without HIV.
-
Primary ovarian insufficiency: a toolkit for the busy clinician. Menopause (IF 2.7) Pub Date : 2023-12-12 Ekta Kapoor
Primary ovarian insufficiency (sometimes known as premature ovarian insufficiency) is a result of loss of ovarian follicular activity before the age of 40 years. It is an endocrine deficiency state in women, characterized by premature estrogen deprivation. In the absence of estrogen replacement, women experience bothersome menopause symptoms and a predisposition to accelerated aging and multimorbidity
-
Anaerobic and aerobic contributions to repeated supramaximal cycling exercises and their adaptation to high-intensity interval training in obese perimenopausal and postmenopausal women. Menopause (IF 2.7) Pub Date : 2023-12-12 Georges Jabbour, Horia D Iancu
This study investigated the anaerobic and aerobic contributions to total energy release during repeated supramaximal cycling exercises (SCE) and their adaptation in response to 6 weeks of high-intensity interval training (HIIT) in obese perimenopausal and postmenopausal women.
-
Menopause: The Journal of The Menopause Society Volume 30, 2023: SUBJECT INDEX. Menopause (IF 2.7) Pub Date : 2023-12-01
-
2023 Annual Meeting of The Menopause Society September 27 - 30, 2023, Philadelphia, PA. Menopause (IF 2.7) Pub Date : 2023-12-01
-
Premature ovarian insufficiency recommendations and ChatGPT. Menopause (IF 2.7) Pub Date : 2023-11-28 Hinpetch Daungsupawong,Viroj Wiwanitkit
-
The association of urinary incontinence and disability among a diverse sample of midlife Study of Women's Across the Nation women. Menopause (IF 2.7) Pub Date : 2023-11-28 Sheila A Dugan, Sybil L Crawford, Karla Wente, L Elaine Waetjen, Carrie Karvonen-Gutierrez, Siobán D Harlow
The aim of the study is to examine whether urinary incontinence (UI) type, frequency, and amount are associated with self-reported disability in a racially/ethnically diverse cohort of community-dwelling midlife women.
-
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause. Menopause (IF 2.7) Pub Date : 2023-11-28 Antonia Morga, Mayank Ajmera, Emily Gao, Oscar Patterson-Lomba, Angela Zhao, Shayna Mancuso, Emad Siddiqui, Risa Kagan
The neurokinin 3 receptor antagonist fezolinetant 45 mg/d significantly reduced frequency/severity of moderate to severe vasomotor symptoms (VMS) of menopause compared with placebo in two phase 3 randomized controlled trials. Its efficacy relative to available therapies is unknown.
-
The association between reproductive period and handgrip strength in postmenopausal women: a nationwide cross-sectional study. Menopause (IF 2.7) Pub Date : 2023-11-28 Sae Rom Lee, Young Hye Cho, Eun Ju Park, Youngin Lee, Jung In Choi, Ryuk-Jun Kwon, Soo Min Son, Sang Yeoup Lee
Menarche and menopause are associated with muscle loss and strength in women. Handgrip strength (HGS) is a reliable measurement method of muscle strength. However, it is unclear whether the entire reproductive period, which encompasses both menarche and menopause, is associated with HGS in postmenopausal women.
-
Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial. Menopause (IF 2.7) Pub Date : 2023-11-21 Kejal Kantarci, Nirubol Tosakulwong, Timothy G Lesnick, Firat Kara, June Kendall-Thomas, Ekta Kapoor, Julie A Fields, Taryn T James, Rogerio A Lobo, JoAnn E Manson, Lubna Pal, Dustin B Hammers, Michael Malek-Ahmadi, Marcelle I Cedars, Frederick N Naftolin, Nanette Santoro, Virginia M Miller, Sherman M Harman, N Maritza Dowling, Carey E Gleason
This study aimed to determine long-term cardiometabolic effects of hormone therapies initiated within 3 years of onset of menopause after a 14-year follow-up study of participants of the Kronos Early Estrogen Prevention Study (KEEPS).
-
Association of ß-glucuronidase activity with menopausal status, ethnicity, adiposity, and inflammation in women. Menopause (IF 2.7) Pub Date : 2023-11-20 Janet L Funk, Betsy C Wertheim, Jennifer B Frye, Robert M Blew, Jennifer Skye Nicholas, Zhao Chen, Jennifer W Bea
Many dietary polyphenols with potential health-promoting benefits undergo hepatic conjugation and circulate as inactive glucuronides that can be cleaved by ß-glucuronidase to reform the bioactive aglycone. Although indirect evidence suggests estrogen may induce ß-glucuronidase, little is known about ß-glucuronidase regulation across women's reproductive lifespan. Correlates of serum ß-glucuronidase
-
Is it time to rethink how menopause is defined? Menopause (IF 2.7) Pub Date : 2023-11-14 Lauren Streicher
-
Correlations among Core Outcomes in Menopause-recommended vasomotor symptom outcomes in MsFLASH trials. Menopause (IF 2.7) Pub Date : 2023-11-14 Janet S Carpenter, Joseph C Larson, Myra S Hunter, Sarah Lensen, Chen X Chen, Katherine A Guthrie
This study aimed to advance understanding of vasomotor symptom (VMS) outcomes measurement using pooled data from three Menopause Strategies Finding Lasting Answers to Symptoms and Health (MsFLASH) trials.